Dr. Harmatz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
747 52nd St
Oakland, CA 94609Phone+1 510-428-3058Fax+1 510-450-5813
Education & Training
- Massachusetts General HospitalFellowship, Gastroenterology, 1979 - 1982
- Los Angeles County-Harbor-UCLA Medical CenterResidency, Pediatrics, 1976 - 1979
- Geisel School of Medicine at DartmouthClass of 1976
Certifications & Licensure
- MI State Medical License 2024 - 2027
- MT State Medical License 2022 - 2026
- NM State Medical License 2023 - 2026
- OH State Medical License 2022 - 2026
- WA State Medical License 2023 - 2026
- AZ State Medical License 2023 - 2025
- CA State Medical License 1977 - 2025
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Gastroenterology
- Join now to see all
Clinical Trials
- Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment Start of enrollment: 2006 Feb 01
- Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase Start of enrollment: 2007 Jul 25
- A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I Start of enrollment: 2009 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 43 citationsCaregiving time in sickle cell disease: Psychological effects in maternal caregiversJudith T. Moskowitz, Ellen Butensky, Paul Harmatz, Elliott Vichinsky, Melvin B. Heyman
Pediatric Blood & Cancer. 2007-01-01 - 190 citationsCardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and managementElizabeth A. Braunlin, Paul Harmatz, Maurizio Scarpa, Beatriz Furlanetto, Christoph Kampmann
Journal of Inherited Metabolic Disease. 2011-07-09 - 26 citationsSafety and physiological effects of two different doses of elosulfase alfa in patients with morquio a syndrome: A randomized, double‐blind, pilot studyBarbara K. Burton, Kenneth I. Berger, Gregory D. Lewis, Mark A. Tarnopolsky, Marsha Treadwell
American Journal of Medical Genetics. Part A. 2015-10-01
Press Mentions
- Rare, Deadly Genetic Disease Successfully Treated in Utero for First TimeNovember 9th, 2022
- BioMarin Announces New and Updated Data at 2021 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting Demonstrating Commitment to Understanding Achondroplasia and Potential Treatment ChoiceApril 15th, 2021
- JCR Pharmaceuticals Announces Approval of IZCARGO® (Pabinafusp Alfa) for Treatment of MPS II (Hunter Syndrome) in JapanMarch 23rd, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: